Introducing Malaysia to medically supervised INRT (Inhaler Nicotine Replacement Therapy)

INRT is a breakthrough innovation designed to support those seeking to overcome nicotine dependence. Our medically supervised approach ensures safe, effective therapy tailored to your needs.

Lumelife Malaysia

Exclusive distributor in Malaysia of the Nicovape® Q range of INRT products

INRT use as a cessation therapy

January 2024’s Cochrane Collaboration states that:

“there is high-certainty evidence that increase quit rates compared to Inhealer nicotine replacement therapy (INRT) and moderate-certainty evidence that they increase quit rates compared to vaping products without nicotine”.

NVPs may be particularly useful for patients who have a history of failed quit attempts using other therapies.

Nicovape® Q is exclusively for therapeutic use by medical practitioners

Australia is the first country to establish a therapeutic access pathway to vaping to for smoking cessation.

Nicovape® Q is the first, and remains the only, INRT distributed exclusively under medical prescription globally.

Prescribers have used Nicovape® Q to help thousands of patients stop smoking and vaping permanently.

Developed and manufactured to the standards expected of medical devices

Liber’s Nicovape® Q offers prescribers an INRT that:

Is appropriate as a medical device for smoking cessation and the management of nicotine dependence; and
Is free from the moral and ethical considerations arising from tobacco industry involvement
Has never been sold as a consumer product in Malaysia or globally.

Have all other quit attempts failed?

For patients with a history of failed attempts to stop smoking, the therapeutic use of INRT, particularly when coupled with ongoing support, shows great promise.